Does SEBELIPASE ALFA Cause Poor venous access? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Poor venous access have been filed in association with SEBELIPASE ALFA (KANUMA). This represents 2.6% of all adverse event reports for SEBELIPASE ALFA.
16
Reports of Poor venous access with SEBELIPASE ALFA
2.6%
of all SEBELIPASE ALFA reports
0
Deaths
4
Hospitalizations
How Dangerous Is Poor venous access From SEBELIPASE ALFA?
Of the 16 reports, 4 (25.0%) required hospitalization, and 1 (6.3%) were considered life-threatening.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SEBELIPASE ALFA. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does SEBELIPASE ALFA Cause?
Pyrexia (59)
Diarrhoea (45)
Vomiting (42)
Off label use (38)
Drug ineffective (27)
Headache (26)
Low density lipoprotein increased (22)
Malaise (22)
Fatigue (19)
Infusion related reaction (19)
What Other Drugs Cause Poor venous access?
VEDOLIZUMAB (1,043)
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
Which SEBELIPASE ALFA Alternatives Have Lower Poor venous access Risk?
SEBELIPASE ALFA vs SECNIDAZOLE
SEBELIPASE ALFA vs SECUKINUMAB
SEBELIPASE ALFA vs SELADELPAR LYSINE
SEBELIPASE ALFA vs SELEGILINE
SEBELIPASE ALFA vs SELENIUM